Highlights enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Market Closed - Nasdaq Other stock markets 21:00:00 27/06/2024 BST			5-day change	1st Jan Change
5.17 ^USD	+0.39%		+10.71%	+0.58%

06-21	EnVeno Medical Corporation Announces Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the VenoValve(R) Pivotal Trial	CI
06-17	EnVVeno Medical Corporation Announces New Interim Venous Ulcer Healing Data from the VenoValve®? Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EnVeno Medical Corporation Announces Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the VenoValve(R) Pivotal Trial	06-21	CI
EnVVeno Medical Corporation Announces New Interim Venous Ulcer Healing Data from the VenoValve®? Pivotal Trial to Be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting	06-17	CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024	04-16	CI
EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial	03-06	MT
EnVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve	03-06	CI
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
EnVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium	11-16	CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23	CI
EnVVeno Medical Corporation Achieves Full Enrollment for VenoValve U.S. Pivotal Trial	06/10/23	CI
EnVVeno Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/07/23	CI
Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study	05/07/23	CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	02/03/23	CI
Envveno Medical Corporation Presents Positive Long-Term, Three-Year Observational Data from A Cohort of Patients That Participated in the Previously Concluded Venovalve First-In-Human Clinical Tria	17/11/22	CI
EnVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study	07/11/22	CI
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	27/10/22	CI
EnVVeno Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	03/08/22	CI
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	29/04/22	CI
EnVVeno Medical Secures US Patent for Manufacturing Method Related to VenoValve	11/04/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Highlights

Filters